Device therapy in hypertrophic cardiomyopathy

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 12, 2010, Pages 1767-1775

  Beadle, Roger ^a   Williams, Lynne ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

dual chamber pacing; hypertrophic cardiomyopathy; implantable cardioverter defibrillator; risk stratification; sudden cardiac death; ventricular arrhythmia

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; MYOSIN BINDING PROTEIN C; TROPONIN T;

ARTIFICIAL HEART PACEMAKER; BLOOD PRESSURE; DEFIBRILLATOR; EXERCISE TOLERANCE; FAMILY; FOLLOW UP; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MUSCLE RESECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESYNCOPE; QUALITY OF LIFE; REVIEW; RISK FACTOR; SCREENING; SUDDEN DEATH; SYNCOPE; TREATMENT INDICATION;

ADULT; ARRHYTHMIAS, CARDIAC; CARDIAC PACING, ARTIFICIAL; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOMYOPATHY, HYPERTROPHIC, FAMILIAL; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 78649660804     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.10.156     Document Type: Review

References (61)

1. Alam M, Dokainish H, Lakkis NM. Hypertrophic obstructive cardiomyopathy-alcohol septal ablation vs. myectomy: a meta-analysis. Eur. Heart J. 30, 1080-1087 (2009).
2. Cannan CR, Reeder GS, Bailey KR, Melton LJ III, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population-based study, 1976 through 1990. Circulation 92, 2488-2495 (1995).
3. Maron BJ, Olivotto I, Spirito P et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 102, 858-864 (2000).
4. Nugent AW, Daubeney PE, Chondros P et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 112, 1332-1338 (2005).
5. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fbrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104, 2517-2524 (2001).
6. Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fbrillation in hypertrophic cardiomyopathy: a longitudinal study. J. Am. Coll. Cardiol. 15, 1279-1285 (1990).
7. Maron BJ, Olivotto I, Bellone P et al. Clinical profle of stroke in 900 patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 39, 301-307 (2002).
8. Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: a profle of 78 patients. Circulation 65, 1388-1394 (1982).
9. McKenna WJ, England D, Doi YL, Deanfeld JE, Oakley C, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: infuence on prognosis. Br. Heart J. 46, 168-172 (1981).
10. Savage DD, Seides SF, Maron BJ, Myers DJ, Epstein SE. Prevalence of arrhythmias during 24-hour electrocardiographic monitoring and exercise testing in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. Circulation 59, 866-875 (1979).
11. Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: association with left ventricular apical aneurysm. Br. Heart J. 61, 178-181 (1989).
12. Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 33, 1596-1601 (1999).
13. Maron BJ, Shen WK, Link MS et al. Effcacy of implantable cardioverter-defbrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342, 365-373 (2000).
14. Boriani G, Rapezzi C, Biff M, Branzi A, Spirito P. Atrial fbrillation precipitating sustained ventricular tachycardia in hypertrophic cardiomyopathy. J. Cardiovasc. Electrophysiol. 13, 954 (2002).
15. Edwards RH, Kristinsson A, Warrell DA, Goodwin JF. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br. Heart J. 32, 219-225 (1970).
16. Frenneaux MP, Counihan PJ, Caforio AL, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 82, 1995-2002 (1990).
17. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 84, 686-696 (1991).
18. Thomson HL, Morris-Thurgood J, Atherton J, Frenneaux M. Reduced cardiopulmonary barorefex sensitivity in patients with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 31, 1377-1382 (1998).
19. Olivotto I, Maron BJ, Montereggi A, Mazzuoli F, Dolara A, Cecchi F. Prognostic value of systemic blood pressure response during exercise in a community-based patient population with hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 33, 2044-2051 (1999).
20. Maron BJ, Piccininno M, Casey SA, Bernabo P, Spirito P. Relation of extreme left ventricular hypertrophy to age in hypertrophic cardiomyopathy. Am. J. Cardiol. 91, 626-628 (2003).
21. Spirito P, Watson RM, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of ventricular tachycardia in hypertrophic cardiomyopathy. Am. J. Cardiol. 60, 1137-1142 (1987). (Pubitemid 18043307)
22. Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 15, 1521-1526 (1990). (Pubitemid 20174311)
23. Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N. Engl. J. Med. 342, 1778-1785 (2000).
24. Elliott PM, Gimeno B Jr, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 357, 420-424 (2001).
25. Mogensen J, Kubo T, Duque M et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J. Clin. Invest. 111, 209-216 (2003).
26. Moolman JC, Corfeld VA, Posen B et al. Sudden death due to troponin T mutations. J. Am. Coll. Cardiol. 29, 549-555 (1997).
27. Spirito P, Autore C, Rapezzi C et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation 119, 1703-1710 (2009).
28. Cecchi F, Olivotto I, Montereggi A, Squillatini G, Dolara A, Maron BJ. Prognostic value of non-sustained ventricular tachycardia and the potential role of amiodarone treatment in hypertrophic cardiomyopathy: assessment in an unselected non-referral based patient population. Heart 79, 331-336 (1998).
29. Spirito P, Rapezzi C, Autore C et al. Prognosis of asymptomatic patients with hypertrophic cardiomyopathy and nonsustained ventricular tachycardia. Circulation 90, 2743-2747 (1994).
30. Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients. J. Am. Coll. Cardiol. 42, 873-879 (2003).
31. Maron MS, Olivotto I, Betocchi S et al. Effect of left ventricular outfow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N. Engl. J. Med. 348, 295-303 (2003). (Pubitemid 36119984)
32. McLeod CJ, Ommen SR, Ackerman MJ et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defbrillator discharge in obstructive hypertrophic cardiomyopathy Eur. Heart J. 28, 2583-2588 (2007).
33. Adabag AS, Maron BJ, Appelbaum E et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 51, 1369-1374 (2008).
34. Bruder O, Wagner A, Jensen CJ et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy J. Am. Coll. Cardiol. 56, 875-887 (2010).
35. O'Hanlon R, Grasso A, Roughton M et al. Prognostic signifcance of myocardial fbrosis in hypertrophic cardiomyopathy J. Am. Coll. Cardiol. 56, 867-874 (2010).
36. Melacini P, Maron BJ, Bobbo F et al. Evidence that pharmacological strategies lack effcacy for the prevention of sudden death in hypertrophic cardiomyopathy Heart 93, 708-710 (2007).
37. Jayatilleke I, Doolan A, Ingles J et al. Long-term follow-up of implantable cardioverter defbrillator therapy for hypertrophic cardiomyopathy. Am. J. Cardiol. 93, 1192-1194 (2004).
38. Gregoratos G, Abrams J, Epstein AE et al. ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). J. Cardiovasc. Electrophysiol. 13, 1183-1199 (2002). (Pubitemid 35379627)
39. Maron BJ, Spirito P, Shen WK et al. Implantable cardioverter- defbrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 298, 405-412 (2007). (Pubitemid 47124061)
40. Lin G, Nishimura RA, Gersh BJ et al. Device complications and inappropriate implantable cardioverter defbrillator shocks in patients with hypertrophic cardiomyopathy. Heart 95, 709-714 (2009).
41. Gilgenkrantz JM, Cherrier F, Petitier H, Dodinot B, Houplon M, Legoux J. [Obstructive cardiomyopathy of the left ventricle with complete auriculo-ventriculrar block. Therapeutic considerations]. Arch. Mal. Coeur Vaiss. 61, 439-453 (1968).
42. Hassenstein P, Wolter HH. [Therapeutic control of a threatening stage of idiopathic hypertrophic subaortic stenosis]. Verh. Dtsch. Ges. Kreislaufforsch. 33, 242-246 (1967).
43. Hassenstein P, Storch HH, Schmitz W. [Results of electrical pacing in patients with hypertrophic obstruction cardiomyopathy (author's translation)]. Thoraxchir. Vask. Chir. 23, 496-498 (1975).
44. Jeanrenaud X, Goy JJ, Kappenberger L. Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 339, 1318-1323 (1992).
45. Jeanrenaud X, Kappenberger L. Regional wall motion during pacing for hypertrophic obstructive cardiomyopathy. Pacing Clin. Electrophysiol. 20, 1673-1681 (1997).
46. Kappenberger L, Linde C, Daubert C et al. Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC Study Group. Eur. Heart J. 18, 1249-1256 (1997).
47. McDonald K, McWilliams E, O'Keeffe B, Maurer B. Functional assessment of patients treated with permanent dual chamber pacing as a primary treatment for hypertrophic cardiomyopathy. Eur. Heart J. 9, 893-898 (1988).
48. McDonald KM, Maurer B. Permanent pacing as treatment for hypertrophic cardiomyopathy. Am. J. Cardiol. 68, 108-110 (1991).
49. Pak PH, Maughan WL, Baughman KL, Kieval RS, Kass DA. Mechanism of acute mechanical beneft from VDD pacing in hypertrophied heart: similarity of responses in hypertrophic cardiomyopathy and hypertensive heart disease. Circulation 98, 242-248 (1998).
50. Leclercq C, Gras D, Le Helloco A, Nicol L, Mabo P, Daubert C. Hemodynamic importance of preserving the normal sequence of ventricular activation in permanent cardiac pacing. Am. Heart J. 129, 1133-1141 (1995).
51. Nishimura RA, Hayes DL, Ilstrup DM, Holmes DR Jr, Tajik AJ. Effect of dual-chamber pacing on systolic and diastolic function in patients with hypertrophic cardiomyopathy. Acute Doppler echocardiographic and catheterization hemodynamic study. J. Am. Coll. Cardiol. 27, 421-430 (1996).
52. Fananapazir L, Cannon RO, III, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and b-adrenergic blocker therapy. Circulation 85, 2149-2161 (1992).
53. Fananapazir L, Epstein ND, Curiel RV, Panza JA, Tripodi D, McAreavey D. Long-term results of dual-chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy. Evidence for progressive symptomatic and hemodynamic improvement and reduction of left ventricular hypertrophy. Circulation 90, 2731-2742 (1994).
54. Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy. A randomized, double-blind, crossover study (M-PATHY). Circulation 99, 2927-2933 (1999).
55. Nishimura RA, Trusty JM, Hayes DL et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J. Am. Coll. Cardiol. 29, 435-441 (1997).
56. Ommen SR, Nishimura RA, Squires RW, Schaff HV, Danielson GK, Tajik AJ. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J. Am. Coll. Cardiol. 34, 191-196 (1999).
57. Galve E, Sambola A, Saldana G et al. Late benefts of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart 96, 352-356 (2010).
58. Megevand A, Ingles J, Richmond DR, Semsarian C. Long-term follow-up of patients with obstructive hypertrophic cardiomyopathy treated with dual-chamber pacing. Am. J. Cardiol. 95, 991-993 (2005).
59. Woo A, Monakier D, Harris L et al. Determinants of implantable defbrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 93(9), 1044-1045 (2007).
60. Syska P, Przybylski A, Chojnowska L et al. Implantable cardioverter-defbrillator in patients with hypertrophic cardiomyopathy: effcacy and complications of the therapy in long-term follow-up. J. Cardiovasc. Electrophysiol. 21(8), 883-889 (2010).
61. Maron BJ, Shen WK, Link MS et al. Effcacy of implantable cardioverter-defbrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N. Engl. J. Med. 342(6), 365-373 (2000).